A-A-54587
14 February 1992
COMMERCIAL ITEM DESCRIPTION
THIABENDAZOLE ORAL SUSPENSION, USP
The General Services Administration has authorized the use of this Commercial Item Description as a replacement for Military Specification MIL-T-37699 which is cancelled.
Salient characteristics:
Shall be Thiabendazole Oral Suspension, USP.
Shall be in accordance with the requirements of the USP.
All ingredients shall be of a pharmaceutical grade.
Shall contain 0.50 gram of Thiabendazole per 5 ml of suspension, within the applicable assay limits for the suspension.
Workmanship. The suspension shall be free from defects which detract from its appearance or impair its serviceability.
Unit. Bottle (BT). One bottle containing 120 ml, as specified, constitutes one unit.
Contractor certification. The contractor shall certify that the product offered meets the salient characteristics of this description and conforms to the producers’ own drawings, specifications, standards, and quality assurance practices. The Government reserves the right to require proof of such conformance prior to first delivery and thereafter as may be otherwise provided for under the provisions of the contract.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business